PT-141 10mg

Description

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from the Melanotan II scaffold through enzymatic modification. The peptide, with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, exhibits preferential agonist activity at the MC3R and MC4R melanocortin receptor subtypes, which are prominently expressed in the central nervous system and play integral roles in the regulation of neuroendocrine signaling, autonomic function, and behavioral neurocircuitry. These receptor subtypes have been the focus of intensive research in hypothalamic biology and limbic system neuroscience.

In laboratory research, PT-141 has been utilized as a selective pharmacological probe for dissecting melanocortin receptor contributions to CNS signaling pathways. Researchers have employed PT-141 in receptor binding displacement assays, functional reporter gene assays, and calcium imaging experiments to characterize its affinity, selectivity, and efficacy profile across the melanocortin receptor family. The structural relationship of PT-141 to other melanocortin ligands, combined with its distinct receptor subtype preferences, makes it a valuable tool for structure-activity relationship studies and receptor mutagenesis experiments in molecular pharmacology programs.

Each vial is supplied as a lyophilized peptide with verified purity and identity documentation. Hot Shawtz provides PT-141 strictly for use in scientific research. It is not intended for human or veterinary use.

FDA DISCLAIMER

The information provided on this website has not been evaluated by the U.S. Food and Drug Administration (FDA). None of the statements herein, nor any of the products offered, are intended to diagnose, treat, cure, or prevent any medical condition.

All products are supplied strictly as laboratory research reagents and are not for human consumption. We do not provide products to patients and do not make any claims regarding medical use.

Hot Shawtz operates solely as a chemical supplier. It is not a compounding pharmacy and does not operate as a compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act.